| Metric | Value (₹ Cr) | vs Q2 FY26 |
|---|---|---|
| Revenue | 78.90 | 11.9% |
| Total Income | 77.25 | 14.7% |
| Expenditure | 83.18 | 10.6% |
| PBT | -5.93 | 135.7% |
| Net Profit | -4.99 | 93.6% |
| OPM | 8.89% | 5.49pp |
| NPM | -6.46% | 3.61pp |
| EPS | 1.04 | 2500.0% |
Gem Aromatics Reports Q3 & 9MFY26 Results: Revenue at Rs 258.7 Cr, EBITDA Margin at 9.4%
27 Jan 2026 · 27 Jan, 5:21 pm
Summary
Gem Aromatics Ltd, a well-established manufacturer of specialty ingredients, essential oils, aroma chemicals, and value-added derivatives, has announced its un-audited financial results for the quarter and nine months ended 31st December 2025. The company's revenue from operations stands at Rs 83.9 Cr for Q3FY26, Rs 258.7 Cr for 9MFY26, with a gross margin of 18.4% and 18.7% respectively. The EBITDA margin stands at 9.1% for Q3FY26 and 9.4% for 9MFY26. The PAT margin is 5.0% for Q3FY26 and 5.7% for 9MFY26.
Key Highlights
- 1
Revenue during Q3FY26 and 9MFY26 remained impacted by external headwinds
- 2
Conditions improved during Q3FY26, with alignment of customer blending requirements leading to better order inquiries
- 3
Gross margins have improved and are trending towards normal levels
- 4
EBITDA margins have also shown improvement
- 5
Reported profitability was impacted by higher depreciation of Rs 8.7 Cr
- 6
Commercial production of WS-23 and WS-03 cooling agents, along with Clove Oil and Eugenol, commenced on 11 December 2025
- 7
The Dahej facility will increase the Company’s total capacity to approximately 16,000 MTPA
- 8
Building on this expansion, diversification remains a core pillar of the Company’s strategy
- 9
Pilot trials for Safranal and Damascones have been completed for Citral derivatives
- 10
Catalyst preparation is underway for Phenol derivatives and expected to be completed by the end of Q4FY26
- 11
The Company remains well positioned to drive long-term value creation and is targeting revenue of Rs 1,050 - 1,100 Cr by FY28, with EBITDA margins of 16 -18%
Management Comments
Mr. Yash Vipul Parekh
MD & CEO
During Q3FY26, the Company commissioned WS 23 & WS 03 cooling agents, along with Clove Oil and Eugenol, at its greenfield Dahej plant, marking an important operational milestone. The plant is currently in the stabilization phase and has successfully completed the first stage audits for FSSC 22000 Version 6, GHP, HACCP, ISO 9001 2015, ISO 14001 2015, and ISO 45001 2018. Gross margins have improved and are trending towards normal levels, and EBITDA margins have also shown improvement, supported by a gradual recovery in mint prices and improved customer blending alignment, which led to better order inquiries during Q3FY26. Non-mint products such as clove and its derivatives continued to grow in line with the Company’s diversification strategy. However, revenues remained impacted by external headwinds. Looking ahead, the Company continues to advance its product pipeline. Pilot trials for Citral derivatives, including Safranal and Damascones, have been completed. For Phenol derivatives, catalyst preparation is underway and is expected to be completed by the end of Q4FY26, with trial production planned from Q1FY27. These initiatives are supporting a gradual reduction in dependence on Mint and Mint derivatives. With an expanding product portfolio, improving asset utilisation, and a continued focus on innovation and sustainability, the Company remains well positioned to drive long-term value creation and is targeting revenue of Rs 1,050 - 1,100 Cr by FY28, with EBITDA margins of 16 -18%.
Informational and educational content only. Not investment advice.